Literature DB >> 24729278

Comparison of renal response parameters for juvenile membranous plus proliferative lupus nephritis versus isolated proliferative lupus nephritis: a cross-sectional analysis of the CARRA Registry.

A Boneparth1, N T Ilowite2.   

Abstract

Lupus nephritis (LN) affects many patients with juvenile systemic lupus erythematosus (SLE) and is a significant cause of disease morbidity. Membranous plus proliferative LN (M + PLN) may represent a more difficult to treat subtype of juvenile LN, compared to isolated proliferative LN (PLN). In this retrospective observational study, we utilized data from the Childhood Arthritis and Rheumatism Research Alliance (CARRA) registry to compare response rates for pediatric M + PLN versus PLN. Response was assessed at the most recent CARRA registry visit gathered ≥6 months after diagnostic kidney biopsy. Estimated glomerular filtration rate (GFR) less than 90 ml/min/1.73 m(2), indicating renal insufficiency, was found in 16.1% of patients with M + PLN and 6.1% of patients with PLN (P = 0.071). We found no significant difference in achievement of response in either hematuria or proteinuria between PLN and M + PLN groups or between subgroups determined by presence of class III vs. class IV proliferative disease. Exposure rates to mycophenolate, cyclophosphamide, and rituximab were similar between groups. Future studies will be necessary to correlate pediatric LN renal histology data with treatment response as well as other disease outcome measures.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  CARRA registry; Lupus; membranous; nephritis; pediatric; proliferative; response

Mesh:

Year:  2014        PMID: 24729278      PMCID: PMC4194184          DOI: 10.1177/0961203314531841

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  23 in total

1.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL).

Authors: 
Journal:  Am J Kidney Dis       Date:  1992-05       Impact factor: 8.860

4.  Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis.

Authors:  C C Najafi; S M Korbet; E J Lewis; M M Schwartz; M Reichlin; J Evans
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

5.  Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

Authors:  R P Sloan; M M Schwartz; S M Korbet; R Z Borok
Journal:  J Am Soc Nephrol       Date:  1996-02       Impact factor: 10.121

6.  Lupus nephritis: prognostic factors in children.

Authors:  D K McCurdy; T J Lehman; B Bernstein; V Hanson; K K King; R Nadorra; B H Landing
Journal:  Pediatrics       Date:  1992-02       Impact factor: 7.124

7.  The long-term outcome of 93 patients with proliferative lupus nephritis.

Authors:  Gabriella Moroni; Silvana Quaglini; Beniamina Gallelli; Giovanni Banfi; Piergiorgio Messa; Claudio Ponticelli
Journal:  Nephrol Dial Transplant       Date:  2007-05-17       Impact factor: 5.992

8.  The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Authors:  Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

9.  Prognostic determinants in lupus nephritis: a long-term clinicopathologic study.

Authors:  J V Donadio; G M Hart; E J Bergstralh; K E Holley
Journal:  Lupus       Date:  1995-04       Impact factor: 2.911

10.  Correlation of renal histology with outcome in children with lupus nephritis.

Authors:  P J Rush; R Baumal; A Shore; J W Balfe; M Schreiber
Journal:  Kidney Int       Date:  1986-05       Impact factor: 10.612

View more
  8 in total

1.  Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.

Authors:  L B Lewandowski; L E Schanberg; N Thielman; A Phuti; A A Kalla; I Okpechi; P Nourse; P Gajjar; G Faller; P Ambaram; H Reuter; G Spittal; C Scott
Journal:  Lupus       Date:  2016-08-19       Impact factor: 2.911

Review 2.  Advances in the care of children with lupus nephritis.

Authors:  Scott E Wenderfer; Natasha M Ruth; Hermine I Brunner
Journal:  Pediatr Res       Date:  2016-11-17       Impact factor: 3.756

Review 3.  Advances in proteomic profiling of pediatric kidney diseases.

Authors:  Timothy D Cummins; Erik A Korte; Sagar Bhayana; Michael L Merchant; Michelle T Barati; William E Smoyer; Jon B Klein
Journal:  Pediatr Nephrol       Date:  2022-02-26       Impact factor: 3.651

Review 4.  Hurdles to the introduction of new therapies for immune-mediated kidney diseases.

Authors:  Hans-Joachim Anders; David R W Jayne; Brad H Rovin
Journal:  Nat Rev Nephrol       Date:  2016-01-25       Impact factor: 28.314

5.  Comparison of Outcomes between Individuals with Pure and Mixed Lupus Nephritis: A Retrospective Study.

Authors:  Titilayo O Ilori; Nosayaba Enofe; Anju Oommen; Jason Cobb; Jose Navarrete; Demilade A Adedinsewo; Oluwatobiloba Oshikoya; Helene Fevrier; Alton B Farris; Laura Plantinga; Akinlolu O Ojo
Journal:  PLoS One       Date:  2016-06-15       Impact factor: 3.240

6.  Familial autoimmunity in the Childhood Arthritis and Rheumatology Research Alliance registry.

Authors:  Sampath Prahalad; Courtney E McCracken; Lori A Ponder; Sheila T Angeles-Han; Kelly A Rouster Stevens; Larry B Vogler; Carl D Langefeld; Susan D Thompson
Journal:  Pediatr Rheumatol Online J       Date:  2016-03-10       Impact factor: 3.054

7.  The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months.

Authors:  Timothy Beukelman; Yukiko Kimura; Norman T Ilowite; Kelly Mieszkalski; Marc D Natter; Grendel Burrell; Brian Best; Jason Jones; Laura E Schanberg
Journal:  Pediatr Rheumatol Online J       Date:  2017-04-17       Impact factor: 3.054

8.  Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE.

Authors:  Mileka Gilbert; Beatrice Goilav; Joyce J Hsu; Paul J Nietert; Esra Meidan; Annabelle Chua; Stacy P Ardoin; Scott E Wenderfer; Emily von Scheven; Natasha M Ruth
Journal:  Pediatr Rheumatol Online J       Date:  2021-08-30       Impact factor: 3.054

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.